MannKind traded at $2.70 this Friday April 24th, decreasing $0.01 or 0.37 percent since the previous trading session. Looking back, over the last four weeks, MannKind lost 18.42 percent. Over the last 12 months, its price fell by 43.04 percent. Looking ahead, we forecast MannKind to be priced at 2.64 by the end of this quarter and at 2.48 in one year, according to Trading Economics global macro models projections and analysts expectations.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.